Objective To compare intra-pleural injection efficacy and safety between Endostar and bevacizumab combined with pemetrexed/cisplatin for the treatment of malignant pleural effusion in patients with epidermal growth fa...Objective To compare intra-pleural injection efficacy and safety between Endostar and bevacizumab combined with pemetrexed/cisplatin for the treatment of malignant pleural effusion in patients with epidermal growth factor receptor(EGFR)-/anaplastic lymphoma kinase(ALK)-lung adenocarcinoma. Methods Sixty-four pCVatients with EGFR-/ALK-lung adenocarcinoma with malignant pleural effusion(MPE) were admitted to the authors' hospital between January 2016 and June 2017. Patients were randomly divided into two groups: Endostar combined with pemetrexed/cisplatin(Endostar group); and bevacizumab plus pemetrexed/cisplatin(Bevacizumab group). They underwent thoracic puncture and catheterization, and MPE was drained as much as possible. Both groups were treated with pemetrexed 500 mg/m^2, intravenous drip(d1), cisplatin 37.5 mg/m^2 per time, intra-pleural injection(d1, d3). Patients in the Endostar group were treated with Endostar 30 mg per time, intra-pleural injection(d1, 3), and patients in the Bevacizumab group were treated with bevacizumab 5 mg/kg per time, intra-pleural injection(d1). Only one cycle of treatment was applied. MPE was extracted before treatment and on day 7 after treatment. The levels of vascular endothelial growth factor(VEGF) were determined using ELISA. Efficacy and side effects were evaluated according to the Response Evaluation Criteria in Solid Tumors(RECIST) version 1.1, and National Cancer Institute Common Terminology Criteria for Adverse Events(CTCAE) version 3.0 criteria. Results The objective response rates in the Endostar and Bevacizumab groups were 50.0% and 56.3%, respectively; there was no statistical difference between the groups(P > 0.05). After one cycle of treatment, the mean VEGF levels in MPE in both groups decreased significantly, and there was no significant difference in the degree of decline between the two groups(P > 0.05). In both groups, pre-treatment VEGF levels for patients achieving complete response were significantly higher than those for patients achieving stable disease + progressive disease(P < 0.05). No specific side effects were recorded. Conclusion Endostar and Bevacizumab demonstrated similar efficacy in controlling MPE in patients with EGFR-/ALK-lung adenocarcinoma through an anti-angiogenesis pathway, with tolerable side effects. The levels of VEGF in MPE could predict the efficacy of intra-pleural injection of anti-angiogenesis drugs.展开更多
Objective: To observe the clinical efficacy of Xiaoshui decoction (XSD,消水方) combined with intrapleural perfusion of cisplatin in the treatment of malignant pleural effusion. Methods: Fifty-one patients with mal...Objective: To observe the clinical efficacy of Xiaoshui decoction (XSD,消水方) combined with intrapleural perfusion of cisplatin in the treatment of malignant pleural effusion. Methods: Fifty-one patients with malignant pleural effusion were randomly assigned to two groups. The treated group patients) received oral administration of XSD combined with intrapleural perfusion of cisplatin, and control group (25 patients) was only treated with intrapleural perfusion of cisplatin. The effects of 26 he he short-term efficacy, quality of life scores and clinical symptom scores of malignant pleural effusion were evaluated. Results: The short-term efficacy in the treated group and the control group was 72.0% and 58.3%, respectively, and no significant difference was found (P〉0.05). In contrast, the quality of life in the treated group was significantly improved compared to that of the control group (P〈0.05), and so was the symptom remission (P〈0.05). Conclusions: The combined therapy of XSD and intrapleural perfusion of cisplatin did not show obvious improvement in short-term efficacy, but the therapy remarkably alleviated the symptoms and improved the quality of life of patients.展开更多
Objective To evaluate the efficacy and safety of lentinan injection plus cisplatin(LIC)in the treatment of malignant pleural effusion(MPE).Methods We searched the database of Cochrane Library,PubMed,EMBASE, ISI Web of...Objective To evaluate the efficacy and safety of lentinan injection plus cisplatin(LIC)in the treatment of malignant pleural effusion(MPE).Methods We searched the database of Cochrane Library,PubMed,EMBASE, ISI Web of Knowledge,Chinese Biomedical Literature Database,Chinese Scientific Journals Full-text Database, Chinese Journal Full-text,and Google Scholar,etc.,up to February 28th,2011 to identify randomized controlled trials(RCTs)about lentinan injection(LI)for MPE,evaluate the quality of the included studies,and analyze the data by Cochrane Collaboration’s RevMan5.0 software.Results Twenty-nine RCTs involving 1831 patients were included.Meta analysis results suggested that there were some differences when comparing LIC with control groups suffering from MPE,for LIC could improve the near-term curative effect and the quality of life to some extent. Besides,compared with chemotherapy alone,LI plus chemotherapy had an advantage in relieving adverse reactions, such as gastrointestinal reactions,myelosuppression,chest pain,and general malaise.Conclusion The current evidence indicates that LI may have adjuvant therapeutic effects for MPE.展开更多
目的系统评价贝伐珠单抗联合顺铂胸腔灌注治疗非小细胞肺癌(NSCLC)合并恶性胸腔积液(MPE)的疗效及安全性。方法检索PubMed、Embase、The Cochrane Library、Web of Science、ProQuest、中国生物医学文献数据库、中国知网、维普、万方数...目的系统评价贝伐珠单抗联合顺铂胸腔灌注治疗非小细胞肺癌(NSCLC)合并恶性胸腔积液(MPE)的疗效及安全性。方法检索PubMed、Embase、The Cochrane Library、Web of Science、ProQuest、中国生物医学文献数据库、中国知网、维普、万方数据库中收录的关于贝伐珠单抗联合顺铂对比顺铂胸腔灌注治疗NSCLC合并MPE的随机对照试验,检索时间均从建库至2022年4月18日。依照Cochrane系统评价方法对纳入的随机对照试验进行质量评价,采用RevMan5.3和Stata15软件进行Meta分析。结果本研究最终纳入14项随机对照试验,共计932例患者。Meta分析结果显示,试验组患者总有效率(RR=1.42,95%CI:1.30~1.54,P﹤0.01)和生活质量改善率(RR=1.57,95%CI:1.27~1.94,P﹤0.01)均明显高于对照组,胸腔积液中血管内皮生长因子(VEGF)水平明显低于对照组(MD=-56.50,95%CI:-67.79~-45.21,P﹤0.01)。试验组和对照组患者胃肠道反应、骨髓抑制、肝肾功能异常、高血压、出血事件发生率比较,差异均无统计学意义(P﹥0.05)。结论贝伐珠单抗联合顺铂胸腔灌注治疗NSCLC合并MPE可提高疗效,抑制MPE生成,同时不增加不良反应发生率。展开更多
基金Supported by a grant from the Nature Science Foundation of Hubei Province,China(No.2017CFB472)
文摘Objective To compare intra-pleural injection efficacy and safety between Endostar and bevacizumab combined with pemetrexed/cisplatin for the treatment of malignant pleural effusion in patients with epidermal growth factor receptor(EGFR)-/anaplastic lymphoma kinase(ALK)-lung adenocarcinoma. Methods Sixty-four pCVatients with EGFR-/ALK-lung adenocarcinoma with malignant pleural effusion(MPE) were admitted to the authors' hospital between January 2016 and June 2017. Patients were randomly divided into two groups: Endostar combined with pemetrexed/cisplatin(Endostar group); and bevacizumab plus pemetrexed/cisplatin(Bevacizumab group). They underwent thoracic puncture and catheterization, and MPE was drained as much as possible. Both groups were treated with pemetrexed 500 mg/m^2, intravenous drip(d1), cisplatin 37.5 mg/m^2 per time, intra-pleural injection(d1, d3). Patients in the Endostar group were treated with Endostar 30 mg per time, intra-pleural injection(d1, 3), and patients in the Bevacizumab group were treated with bevacizumab 5 mg/kg per time, intra-pleural injection(d1). Only one cycle of treatment was applied. MPE was extracted before treatment and on day 7 after treatment. The levels of vascular endothelial growth factor(VEGF) were determined using ELISA. Efficacy and side effects were evaluated according to the Response Evaluation Criteria in Solid Tumors(RECIST) version 1.1, and National Cancer Institute Common Terminology Criteria for Adverse Events(CTCAE) version 3.0 criteria. Results The objective response rates in the Endostar and Bevacizumab groups were 50.0% and 56.3%, respectively; there was no statistical difference between the groups(P > 0.05). After one cycle of treatment, the mean VEGF levels in MPE in both groups decreased significantly, and there was no significant difference in the degree of decline between the two groups(P > 0.05). In both groups, pre-treatment VEGF levels for patients achieving complete response were significantly higher than those for patients achieving stable disease + progressive disease(P < 0.05). No specific side effects were recorded. Conclusion Endostar and Bevacizumab demonstrated similar efficacy in controlling MPE in patients with EGFR-/ALK-lung adenocarcinoma through an anti-angiogenesis pathway, with tolerable side effects. The levels of VEGF in MPE could predict the efficacy of intra-pleural injection of anti-angiogenesis drugs.
文摘Objective: To observe the clinical efficacy of Xiaoshui decoction (XSD,消水方) combined with intrapleural perfusion of cisplatin in the treatment of malignant pleural effusion. Methods: Fifty-one patients with malignant pleural effusion were randomly assigned to two groups. The treated group patients) received oral administration of XSD combined with intrapleural perfusion of cisplatin, and control group (25 patients) was only treated with intrapleural perfusion of cisplatin. The effects of 26 he he short-term efficacy, quality of life scores and clinical symptom scores of malignant pleural effusion were evaluated. Results: The short-term efficacy in the treated group and the control group was 72.0% and 58.3%, respectively, and no significant difference was found (P〉0.05). In contrast, the quality of life in the treated group was significantly improved compared to that of the control group (P〈0.05), and so was the symptom remission (P〈0.05). Conclusions: The combined therapy of XSD and intrapleural perfusion of cisplatin did not show obvious improvement in short-term efficacy, but the therapy remarkably alleviated the symptoms and improved the quality of life of patients.
基金The National College Students’Innovative Experiment Project of Lanzhou University(101073034)The Fundamental Research Funds for the Central Universities(lzujbky-2011-133)
文摘Objective To evaluate the efficacy and safety of lentinan injection plus cisplatin(LIC)in the treatment of malignant pleural effusion(MPE).Methods We searched the database of Cochrane Library,PubMed,EMBASE, ISI Web of Knowledge,Chinese Biomedical Literature Database,Chinese Scientific Journals Full-text Database, Chinese Journal Full-text,and Google Scholar,etc.,up to February 28th,2011 to identify randomized controlled trials(RCTs)about lentinan injection(LI)for MPE,evaluate the quality of the included studies,and analyze the data by Cochrane Collaboration’s RevMan5.0 software.Results Twenty-nine RCTs involving 1831 patients were included.Meta analysis results suggested that there were some differences when comparing LIC with control groups suffering from MPE,for LIC could improve the near-term curative effect and the quality of life to some extent. Besides,compared with chemotherapy alone,LI plus chemotherapy had an advantage in relieving adverse reactions, such as gastrointestinal reactions,myelosuppression,chest pain,and general malaise.Conclusion The current evidence indicates that LI may have adjuvant therapeutic effects for MPE.
文摘目的系统评价贝伐珠单抗联合顺铂胸腔灌注治疗非小细胞肺癌(NSCLC)合并恶性胸腔积液(MPE)的疗效及安全性。方法检索PubMed、Embase、The Cochrane Library、Web of Science、ProQuest、中国生物医学文献数据库、中国知网、维普、万方数据库中收录的关于贝伐珠单抗联合顺铂对比顺铂胸腔灌注治疗NSCLC合并MPE的随机对照试验,检索时间均从建库至2022年4月18日。依照Cochrane系统评价方法对纳入的随机对照试验进行质量评价,采用RevMan5.3和Stata15软件进行Meta分析。结果本研究最终纳入14项随机对照试验,共计932例患者。Meta分析结果显示,试验组患者总有效率(RR=1.42,95%CI:1.30~1.54,P﹤0.01)和生活质量改善率(RR=1.57,95%CI:1.27~1.94,P﹤0.01)均明显高于对照组,胸腔积液中血管内皮生长因子(VEGF)水平明显低于对照组(MD=-56.50,95%CI:-67.79~-45.21,P﹤0.01)。试验组和对照组患者胃肠道反应、骨髓抑制、肝肾功能异常、高血压、出血事件发生率比较,差异均无统计学意义(P﹥0.05)。结论贝伐珠单抗联合顺铂胸腔灌注治疗NSCLC合并MPE可提高疗效,抑制MPE生成,同时不增加不良反应发生率。